New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine

Holzkirchen, March 6, 2017 /PRNewswire/ — Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today presented data for its proposed biosimilar adalimumab (GP2017). The Phase 3 confirmatory efficacy, safety and immunogenicity study met its primary endpoint demonstrating GP